nanoTherics finalist in the Engineer Technology and Innovation Awards 2008
The Engineer Technology & Innovation Awards recognise and reward excellence in collaboration between the UK’s universities and some of its most dynamic companies. This prestigious awards scheme invites university engineering and technology departments and their partners in industry to step into the spotlight with outstanding examples of collaborative activity. The awards ceremony is being held on 3rd October 2008. See http://www.theengineerawards.co.uk/ for more details.
nanoTherics shortlisted for Lord Stafford Awards 2008
nanoTherics has been selected as a finalist for the 2008 Lord Stafford Awards. The company is a finalist in the "Impact Through Innovation" category. The awards ceremony will be held on 13th November 2008. See http://www.lordstaffordawards.com for more details.
visit nanoTherics at the Magnetic Carriers and the UK Cell and Tissue Engineering Society meetings
nanoTherics will be exhibiting and presenting results of our research at the “Scientific and Clinical Applications of Magnetic Carriers” meeting in Vancouver, Canada in May, 2008 and at the “UK Cell and Tissue Engineering Society” meeting in Nottingham in July, 2008. Drop by to hear more about our technology.
nanoTherics in the news…
nanoTherics has been featured in articles on the Dow Jones Venture Wire, The Manufacturing Chemist, Real Deals, Tornado Insider, The Stoke Sentinel and others.
nanoTherics completes investment with Mercia
Press Release (May 7, 2008) The Mercia Technology Seed Fund, a leading provider of venture capital to early stage technology-backed businesses in the West Midlands, has just completed an investment into nanoTherics for a significant minority equity stake in the business. This scientific medical devices company was founded following cutting edge biomedical research conducted at Keele University and the University of Florida.
nanoTherics’s primary business is the supply of scientific devices and associated products to research laboratories, both in the pharmaceutical and biotechnology industries and academia. Early sales demonstrate a strong market appetite for the solution presented by the patented technology which uses nanoparticles and magnetic fields to facilitate delivery of important molecules, such as DNA, into living cells. The medium to long-term opportunity for this approach relates to non-viral gene therapy, an area now demanding safe technology to treat genetic diseases such as cystic fibrosis.
Dr Mark Payton commented “nanoTherics is a compelling example of a new wave of commercial opportunities emerging from the university sector where by working closely with our partner universities, such as Keele University, we are able to accelerate the commercial development of key disruptive technologies.”
Dr Neil Farrow, COO of nanoTherics, added: “We are delighted to be working alongside MTSF, a fund highly experienced in growing early stage technology companies such as nanoTherics.”